Adverse, histaminoid-type reactions have been reported after the administration of anesthetics, such as alfaxalone, solubilized in non-ionic, aqueous surfactants. These side effects may be reduced or eliminated by combining the primary inducing agent, alfaxalone, with cyclodextrins which have been demonstrated to improve solubility for other steroids. Studies resulting from Phase I show promise for this combination. Successful development of this formulation will provide a safe alternative for the currently marketed dosage form in the guise of a non-surfactant formulation for the inducing agent. This preparation should result in a reduction in allergic side effects, thereby allowing safe and reliable anesthesia.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44GM043660-03
Application #
3507985
Study Section
Special Emphasis Panel (SSS (B))
Project Start
1990-03-01
Project End
1994-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Pharmos Corporation
Department
Type
DUNS #
City
Alachua
State
FL
Country
United States
Zip Code
32615